Background and Aims: Vitamin D insufficiency is prevalent in individuals with inflammatory bowel disease [IBD], as well as in pregnant women; however, the prevalence of vitamin D insufficiency in pregnant women with IBD is unknown. This study assessed the prevalence of vitamin D insufficiency in pregnant women with IBD and the adequacy of recommended supplementation. Methods: A cross-sectional study was conducted in pregnant women with inflammatory bowel disease [Crohn's disease = 61, ulcerative colitis = 41] and without inflammatory bowel disease [n = 574]. Chi square tests and log binomial regression were used to examine the prevalence of vitamin D insufficiency. Covariates included ethnicity and season. Adequacy of vitamin D supplementation during pregnancy was also assessed. 
Introduction
The incidence and prevalence of inflammatory bowel disease [IBD] , consisting of Crohn's disease [CD] and ulcerative colitis [UC] , is increasing worldwide. [1] [2] [3] Europe has one of the highest reported prevalences of IBD, with 322 per 100 000 persons affected with CD in Germany and 505 per 100 000 persons affected with UC in Norway. [1] [2] [3] [4] Similarly to Europe, North America has also has the highest prevalence of IBD, with 319 per 100 000 persons affected with CD in Canada and 286 per 100 000 persons affected with UC in the USA. [1] [2] [3] [4] Given that the onset and diagnosis peak between 18 and 35 years of age, 5 IBD may be of a greater concern for females as the peak coincides with their prime reproductive years. Studies have consistently demonstrated an association between disease activity [particularly at conception] and adverse pregnancy outcomes including preterm birth and delivery of small for gestational age infants. [6] [7] [8] Since these adverse pregnancy outcomes can predispose infants to morbidity later in life such as type 2 diabetes and cardiovascular disease, 9 ,10 studying potentially preventable factors for adverse pregnancy outcomes-apart from disease control-in the IBD population is important.
One such modifiable risk factor for adverse pregnancy outcomes is vitamin D insufficiency. Lower levels of vitamin D have been independently associated with increased materno-foetal-related morbidity in the general population, including preeclampsia, preterm birth, and delivery of small for gestational age infants. [11] [12] [13] [14] Vitamin D, a micronutrient, can be obtained through exposure to sunlight as cholecalciferol [D3] or through a natural and fortified diet in the form of ergocalciferol [D2] . 15, 16 Individuals who are unable to obtain sufficient vitamin D through these sources can increase their vitamin D concentrations with exogenous supplementation of D2 or D3. 15, 16 Vitamins D2 and D3 are absorbed in the proximal part of the small intestine and go through a chain of metabolic reactions starting at the liver, and then in the kidney. 16 Vitamin D insufficiency is common with varying prevalences of vitamin D insufficiency globally, depending on various factors including geographical location, season, time of day, skin pigmentation, sunscreen use, smoking status, calcium intake and body mass index [BMI] . [17] [18] [19] [20] Pregnant women who are vitamin D insufficient are at increased risk of numerous pregnancy-related health issues including preeclampsia, gestational diabetes, and preterm birth. 21 The prevalence of vitamin D insufficiency in the general population of pregnant women ranges between 20% and 65%. [22] [23] [24] [25] [26] However, non-pregnant individuals with IBD have a higher prevalence of vitamin D insufficiency than the general population for various reasons, including inflammation or surgical resection leading to malabsorption, decreased oral intake, or inadequate sunlight exposure. 16, 19, 27 The prevalence of vitamin D insufficiency in individuals with CD ranges from 22% to 83% and between 15% and 55% in those with UC. [28] [29] [30] [31] [32] However, the prevalence of vitamin D insufficiency has not been established in pregnant women with IBD.
As vitamin D insufficiency is treatable with supplementation, documenting the prevalence of vitamin D insufficiency in pregnant women with IBD and examining the adequacy of supplementing with vitamin D using current guidelines are crucial in optimising care of this vulnerable population. Therefore, we set out to compare the vitamin D status of pregnant women with and without IBD.
Materials and Methods
This cross-sectional study used two pregnancy cohorts from Alberta, Canada: the research registry of the IBD Pregnancy Clinic at the Clinical characteristics including disease severity, location/extent, duration, and behaviour were captured in women with CD and those with UC. Disease severity was defined using the validated clinical indices for IBD (the HarveyBradshaw Index [HBI] 39 for those with CD; the Simple Clinical Colitis Activity Index [SCCAI] 40 for those with UC). Clinical remission was defined as HBI <5 or SCCAI <3, and clinical relapse as HBI ≥5 or SCCAI ≥3. Phenotyping for disease location, extent, and behaviour was based on the Montreal Classification of IBD. 41 Disease duration was defined as the period from first diagnosis of IBD to the date of blood examinations during pregnancy [<10 vs ≥10 years].
Vitamin D dosing was based on supplementation guidelines authored by the Institute of Medicine, 42, 43 Health Canada, 44 and Dietitians of Canada, 45 which recommend daily vitamin D supplementation of ≥400 IU/day for all pregnant women. This is based on the recommended daily allowance of vitamin D of 600 IU/day and with the assumption that individuals obtain 200 IU of vitamin D per day from diet. The Institute of Medicine 42, 43 and the USES Guideline Committee 37 recommend a daily dosage of vitamin D supplementation of 2000 IU/day for pregnant women at risk of vitamin D deficiency, which is defined by the current literature describing risk factors for vitamin D deficiency. A p-value of <0.05 indicated statistical significance. Log-binomial multivariate logistic regression modelling with a Poisson distribution was used to assess the relative risk of vitamin D insufficiency adjusting for ethnicity and season. Subgroup analyses were conducted for women with CD and UC to determine whether clinical characteristics of IBD were associated with vitamin D insufficiency. Sensitivity analyses were conducted on women who reported the level of vitamin D supplementation separately for those with and without IBD, using cut-offs of 400 IU/day and 2000 IU/day. Listwise deletion was used to exclude missing data.
Statistical analysis

Results
Population
The study population of 676 women with singleton pregnancies consisted of 574 
Clinical characteristics
Phenotypic data of the women with CD and UC can be found in Supplementary Tables 2 and 3, available Table 3 ]. Individuals with CD of longer disease duration [≥10 years] were more likely to be vitamin 
Discussion
In this cross-sectional observational study, we demonstrated that pregnant women with IBD were at a greater risk for vitamin D insufficiency than pregnant women without IBD. The majority of the literature reports a higher prevalence of vitamin D insufficiency in the non-pregnant cohort with IBD compared with the general population. 16, 29, 32, [46] [47] [48] However, a few studies have not supported this, suggesting that the prevalence of vitamin D insufficiency is not statistically different between non-pregnant individuals with IBD and healthy controls. 38, 49, 50 The differences in these findings may be due to a variety of confounding factors including the definition of vitamin D insufficiency [i.e. different thresholds] and differences in the geographical locations of the studies. Irrespective of this, the existing literature only presents data on non-pregnant individuals with IBD, and our study is the first to assess the prevalence of vitamin D insufficiency in pregnant women with IBD. There was a numerical but non-significant increased prevalence of vitamin D insufficiency in pregnant women with UC compared with those with CD. Our findings may be influenced by detection bias, where physicians were more likely to screen and subsequently supplement individuals with CD, based on the premise that vitamin D absorption occurs predominantly in the proximal small intestine. 16, [28] [29] [30] [31] [32] The current guidelines for vitamin D supplementation recommends vitamin D supplementation of 400 IU/day for all pregnant women. [42] [43] [44] [45] However, the guidelines relating to vitamin D supplementation for pregnant women with IBD are as clear. Our study determined that 72.1% of pregnant women with CD and 80.0% of pregnant women with UC were compliant in meeting the minimum daily dosage of 400 IU of vitamin D per day; however, a large proportion of women with IBD were still vitamin D insufficient. This was congruent with a study conducted by Suibhne et al. 50 34, 51, 52 it is important that health care professionals are aware that despite taking either more than 400 IU/day or 2000 IU/day of vitamin D supplements, a significant proportion of pregnant women with IBD remain vitamin D insufficient. The current guidelines should change accordingly to be more explicit in their recommendations, and even higher recommended doses may be required.
This cross-sectional study design using two defined pregnancy cohorts was appropriate and adequately powered to determine the prevalence of vitamin D insufficiency. Further, the cohorts were obtained from the same geographical region, which allowed for consistency in the sunlight exposure throughout each season. A limitation was the inability to adjust for individual outdoor exposure. Further, the cross-sectional study design did not allow for an association between vitamin D status and pregnancy outcomes to be made, and another study design using population-based administrative data may better answer whether increasing vitamin D supplementation will improve pregnancy or clinical outcomes. Future studies may prospectively assess the optimal daily dosage of vitamin D supplementation for pregnant women with IBD and capture data on pregnancy outcomes.
It is acknowledged that our study's findings may only be generalisable to Caucasian pregnant women >30 years of age, with a higher socioeconomic status [SES] . However, the existing literature shows that Caucasian pregnant women and those of higher SES are more likely to be vitamin D sufficient. 53, 54 Therefore, the risk calculated in this study may be lower than the true value of the association. This makes our findings more important, as the risk for vitamin D insufficiency may be even greater in pregnant women with IBD. Potential residual confounding includes cigarette smoking status and pre-pregnancy BMI. Cigarette smoking is associated with lower circulating vitamin D levels, increasing the risk of vitamin D insufficiency. 20, [55] [56] [57] Further, non-pregnant individuals with CD who are smokers are more likely to have active IBD, 58, 59 though smoking has controversially been associated with protective effects in those with UC. 58, 60 We were unable to assess for the potential confounder of smoking, as the total number of current [n = 1] and former [n = 56] smokers in this pregnant cohort was too small to model. This was not unexpected, as smoking is less common in the pregnancy state. 61 Further, we were limited to assessing changes in vitamin D levels during pregnancy. Women are found to be more vitamin D insufficient during the first trimester than the third trimester 62 ; however, our cross-sectional study only measured the vitamin D levels at trimester two or three. This makes our findings even more important, as there was a high prevalence of vitamin D insufficiency in women with IBD who had their vitamin D measured during trimester two or three.
Our study concludes that pregnant women with IBD have a higher prevalence of vitamin D insufficiency [25- 
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